U.S. Biotech Stock News

Palantir Technologies (PLTR) heads into its upcoming earnings report with expectations shaped by rising demand for its AI software, renewed U.S. government interest, and recent participation in high profile AI alliances. See our latest analysis for Palantir Technologies. Recent headlines around Palantir Technologies, from the renewed U.S. Small Business Administration fraud detection work to fresh AI alliance activity, have arrived alongside a 16.47% 30 day share price return. At the same...

Earlier in July 2026, Equinix, Inc. confirmed the planned departure of Chief Business Officer Jon Lin and outlined a transition plan distributing his responsibilities across the senior leadership team while preparing to appoint a new Chief Product Officer. Shortly afterward, the company named Chris Audie as Chief Product Officer and Bruce Owen as Executive Vice President, Global Markets, underscoring a sharpened focus on product innovation and global operations alignment. Next, we’ll examine...

Sarepta Therapeutics has appointed Michael Severino, M.D., a veteran of AbbVie, Amgen, Merck and most recently Tessera Therapeutics, as its Chief Executive Officer effective July 28, 2026, succeeding Douglas Ingram. By combining the CEO role with a seat on Sarepta’s board, Severino’s broad R&D and corporate strategy background could shape how the company prioritizes its gene therapy and RNA-based rare disease programs. Next, we’ll explore how bringing former AbbVie president Michael Severino...

After a 37.8% return over the past year, Best Buy stock no longer looks like an obvious bargain, and the current checks suggest pricing that is roughly in line with what its fundamentals support rather than clearly cheap or clearly expensive. The 37.8% one year gain puts recent shareholders in a strong position, which can make fresh entries more sensitive to what is already baked into the price. Leadership changes, including a new CEO and a chief fulfillment and operations officer focused on...

Earlier in July 2026, ACADIA Pharmaceuticals announced that the FDA granted Fast Track designation to remlifanserin, its investigational 5-HT2A inverse agonist for hallucinations and delusions in Alzheimer’s disease psychosis, alongside progress updates on the seamless Phase 2/3 RADIANT program. This designation, coupled with ongoing Phase 3 enrollment, highlights how remlifanserin could meaningfully expand ACADIA’s late-stage CNS portfolio beyond its current commercial drugs. Next, we’ll...

Snowflake stock sits at the center of a clear valuation tension, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to roughly 41.0% upside relative to the market price, while market based multiples lean the other way and the broader checks flag the shares as far from a straightforward bargain. Snowflake has returned 53.6% over the past 3 years, which puts extra weight on whether current buyers are paying a premium for that track record. Recent AI focused...

Dime Commercial Bancshares, Inc. reported its second-quarter 2026 results with net interest income of US$115.19 million and net income of US$34.81 million, both higher than a year earlier, while also declaring a quarterly US$0.34375 dividend on its 5.50% Series A preferred stock payable on August 14, 2026. The combination of stronger core earnings and the continuation of preferred dividends highlights the bank’s capacity to support income-focused investors while reinforcing its capital...

The new content partnership between NBCUniversal’s Peacock and YouTube Premium has pushed streaming distribution into fresh territory, and investors in digital entertainment are watching closely. By folding Peacock’s full library, including NFL and NBA rights, into YouTube Premium from early 2027, the deal links one of the largest video platforms with a growing subscription service. It also points to new ways of sharing content, advertising, and revenue across platforms. This article walks...

Earlier this week, Biohaven disclosed that a federal jury awarded the company US$1,000,000 in damages in a trade secret lawsuit against Avilar Therapeutics and RA Capital Management. The verdict underscores the legal weight behind Biohaven’s efforts to safeguard its intellectual property, a core asset for any research‑driven biopharmaceutical business. Next, we’ll examine how this courtroom win on intellectual property protection shapes Biohaven’s broader investment narrative over the coming...

New tariffs of 10% to 12.5% on nearly all US trade are shaking up global supply chains, and that puts a fresh spotlight on stocks with ties to domestic manufacturing and onshoring. For investors, the question is which companies might benefit from production rooted closer to home and which could face higher costs or pressure on margins as trade rules tighten. This article breaks down how the latest Section 301 tariffs could matter for your portfolio and profiles 3 stocks from our US Domestic...

Ohio Valley Banc (OVBC) has released its Q2 2026 results, with revenue of about US$14.8 million and EPS of roughly US$0.62, while trailing twelve month revenue sits at around US$62.4 million and EPS at about US$3.02, alongside net income of roughly US$14.2 million over that period. The company has seen quarterly revenue and EPS move within a relatively tight band over recent periods, from about US$16.2 million and US$0.89 in Q2 2025 to around US$14.8 million and US$0.62 in the latest quarter...

Costco Wholesale stock is coming off a strong run, with a 134.1% return over the past 5 years, yet its current valuation appears expensive rather than a clear bargain. Over 5 years, Costco Wholesale has returned 134.1%, which puts recent short-term moves into the context of a stock that has already rewarded long-term holders. Investor focus on Costco Wholesale's use of AI to improve inventory and supply chain efficiency can support expectations for resilient profitability. However,...

Ensign Group (ENSG) opened Q2 2026 with total revenue of US$1.4 billion and basic EPS of US$1.72, as part of a trailing twelve month profile that includes US$5.5 billion in revenue and EPS of US$6.57, alongside reported earnings growth of 17.3% over the past year. The company has seen revenue move from US$1.23 billion in Q2 2025 to US$1.44 billion in Q2 2026, with quarterly EPS rising from US$1.48 to US$1.72 over the same period. This sets up a results season in which net margin trends and...

Medtronic (MDT) is back in focus after initiating a voluntary Class II recall of its DLP One-Piece Pediatric Arterial Cannula, following two complaints about loose foreign material containing trace levels of blood. See our latest analysis for Medtronic. At a share price of US$84.22, Medtronic's recent 1 month share price return of 4.0% contrasts with a year to date share price return that is down 12.3%, while the 3 year total shareholder return of 5.9% points to relatively modest longer term...

DENTSPLY SIRONA (XRAY) has returned to investors’ radar after recent trading data highlighted a mixed performance, with the stock trading near US$13 and returns differing significantly between the past month and the past year. See our latest analysis for DENTSPLY SIRONA. The recent move to a 1-month share price return of 18.26% and a year-to-date share price return of 15.53% suggests momentum in DENTSPLY SIRONA is improving, even though the 1-year total shareholder return declined 16.73% and...

Burke & Herbert Financial Services Corp. previously reported second-quarter 2026 results, with net interest income rising to US$93.05 million while net income fell to US$9.49 million, and the board declared a US$0.55 per share cash dividend payable on September 1, 2026. The combination of stronger net interest income but much lower earnings per share compared with a year earlier highlights pressures on overall profitability even as core lending revenue grows. Next, we’ll consider how this...

New US tariffs of 10% to 12.5% on almost all imports are reshaping the playing field for consumer stocks, putting pressure on import heavy business models while potentially opening the door for companies that make more of their goods at home. For investors, the key question is which stocks could see relatively better conditions if import costs stay elevated or volatile. This article breaks down three US consumer goods stocks from the US Import Substitute Consumer Goods Stocks screener that...

In July 2026, Capricor Therapeutics disclosed that FDA reviewers found no statistically significant benefit for its Duchenne muscular dystrophy cell therapy Deramiocel versus placebo and raised concerns about post-hoc changes to the Phase 3 HOPE-3 trial’s statistical analysis plan, ahead of an advisory committee review. At the same time, Capricor agreed a long-term, FDA-approval‑contingent lease for a 171,000‑square‑foot San Diego headquarters that ties future manufacturing expansion...

CrowdStrike Holdings (NasdaqGS:CRWD) joined Nvidia and other partners to launch an open-source AI cybersecurity alliance. The alliance aims to build shared AI security tools and standards for defending against cyber threats. CrowdStrike also expanded its partnership with Schwarz Digits to provide sovereign EU security solutions to European enterprises. CrowdStrike operates as a cloud-based cybersecurity company focused on endpoint, identity and cloud workload protection, which ties directly...

Global inflation trends, energy price swings and shifting central bank policies are pushing investors to look more closely at companies where analysts see healthy earnings growth potential and balance sheets that can cope with bumps in the road. The Healthy high growth potential screener focuses on stocks that meet both of these tests, so you are not just chasing growth at any price. In this article you will see 3 of the best stocks from this screener, giving you a focused starting list if...

Recently, Braze (NASDAQ:BRZE) reported that its customer engagement platform continues to gain traction, with billings rising an average of 32.1% over the past year and management signaling a positive sales outlook for the next 12 months. This performance, alongside evidence of efficient customer acquisition and clear product‑market fit, suggests Braze’s business model is scaling effectively in personalized, cross‑channel marketing. Next, we’ll examine how this strong billings growth and...

GameStop (GME) shares are back in focus after the company joined forces with Uber Eats, allowing customers to order consoles, games, accessories, and collectibles for scheduled or on demand delivery across the United States. See our latest analysis for GameStop. The Uber Eats partnership lands at a time when GameStop’s 1 day share price return of 1.65% contrasts with a 90 day share price return that is down 14.23% and a 1 year total shareholder return that is down 5.25%, pointing to pockets...

Citizens Community Bancorp (CZWI) just posted Q2 2026 results with total revenue of US$11.8 million and basic EPS of US$0.11, alongside trailing twelve month revenue of US$58.3 million and EPS of US$1.31. Over recent quarters the company has seen revenue move from US$14.8 million in Q2 2025 to US$15.6 million in Q4 2025 and US$15.4 million in Q1 2026, while quarterly EPS ranged between US$0.32 and US$0.44 before landing at US$0.11 in the latest period. This sets up a results season in which...

Why the IDE892 trial update matters for IDEAYA Biosciences stock IDEAYA Biosciences (IDYA) has moved IDE892 into Part 2 monotherapy expansion in its Phase 1/2 trial for MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic ductal adenocarcinoma. See our latest analysis for IDEAYA Biosciences. The IDE892 trial update lands at a time when IDEAYA Biosciences’ share price has shown firm momentum, with a 26.62% 90-day share price return and a 46.96% 1-year total...